C
CTABF
vs
S&P 500
S&P 500
Over the past 12 months, CTABF has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
CTABF vs S&P 500
Performance Gap
CTABF vs S&P 500
Performance By Year
CTABF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Canntab Therapeutics Ltd
Glance View
Canntab Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-04-21. The firm is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The firm operates in one reportable operating, being engaged in the medical marijuana business. All property and equipment, right-of-use assets and intangible assets are located in Canada. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. The company holds cannabis standard processing and sales for medical purposes license, a cannabis research license, and an industrial hemp license from health Canada.
